Daniel Benjamin Mark, MD

Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail 2400 Pratt St, Durham, NC 27705
Phone (919) 668-8775
Email address mark0004@mc.duke.edu

Dr. Mark is a clinical cardiologist with the rank of Professor of Medicine (with tenure) as well as Vice Chief for Academic Affairs in the Division of Cardiology, Department of Medicine at Duke University Medical Center. He is also the Director of Outcomes Research at the Duke Clinical Research Institute. He has been on the full-time faculty at Duke since 1985. Prior to that he completed his cardiology fellowship at Duke, his residency and internship at the University of Virginia Hospital, and received his medical degree from Tufts University and his Master’s degree from Harvard. In 1998, he was given the honor of being elected to the American Society for Clinical Investigators and in 2002 he was honored by election to the Association of American Physicians. These organizations are the two most prestigious honor societies in academic medicine. In 2009, Dr. Mark was awarded the American College of Cardiology Distinguished Scientist Award.

Dr. Mark's major research interests include medical economics and quality of life outcomes, outcomes research, and quality of medical care. Currently, Dr. Mark is directing a number of outcomes analyses for ongoing clinical trials including PROMISE (anatomic versus functional testing for coronary artery disease, NIH), CABANA (catheter ablation versus antiarrhythmic drug therapy for atrial fibrillation, NIH), ISCHEMIA (percutaneous coronary intervention versus optimal medical therapy for moderate-severe ischemia), and STICH (CABG +/- ventricular reconstruction versus medical therapy for ischemic heart disease, NIH). He was the principal author of the AHCPR Unstable Angina Guidelines and is a co-author of both the American College of Cardiology Guideline on Exercise Testing and their Coronary Stent Consensus Guideline. He is also the Editor of the American Heart Journal. Dr. Mark has published over 270 peer-reviewed articles, two books, and 80 book chapters. He lectures widely in the US, as well as in Canada, South America, and Europe.

Keywords: cost-effectiveness analysis, disease management, quality of life assessment, resource use.

Education and Training

  • M.D., Tufts University, 1978

Publications

Stewart, RAH, Szalewska, D, She, L, Lee, KL, Drazner, MH, Lubiszewska, B, Kosevic, D, Ruengsakulrach, P, Nicolau, JC, Coutu, B, Choudhary, SK, Mark, DB, Cleland, JGF, Piña, IL, Velazquez, EJ, Rynkiewicz, A, and White, H. "Exercise Capacity and Mortality in Patients With Ischemic Left Ventricular Dysfunction Randomized to Coronary Artery Bypass Graft Surgery or Medical Therapy. An Analysis From the STICH Trial (Surgical Treatment for Ischemic Heart Failure)." JACC: Heart Failure 2, no. 4 (January 1, 2014): 335-343.

Full Text

Felker, GM, Ahmad, T, Anstrom, KJ, Adams, KF, Cooper, LS, Ezekowitz, JA, Fiuzat, M, Houston-Miller, N, Januzzi, JL, Leifer, ES, Mark, DB, Desvigne-Nickens, P, Paynter, G, Piña, IL, Whellan, DJ, and O'Connor, CM. "Rationale and design of theguide-it study: Guiding evidence based therapy usingbiomarker intensified treatment inheart failure." Jacc: Heart Failure 2, no. 5 (January 1, 2014): 458-465.

Full Text

Steinberg, BA, Al-Khatib, SM, Edwards, R, Han, JY, Bardy, GH, Bigger, JT, Buxton, AE, Moss, AJ, Lee, KL, Steinman, R, Dorian, P, Hallstrom, A, Cappato, R, Kadish, AH, Kudenchuk, PJ, Mark, DB, Inoue, LYT, and Sanders, GD. "Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: Results from a combined analysis of 4 randomized clinical trials." JACC: Heart Failure 2, no. 6 (January 1, 2014): 623-629.

Full Text

Escolar, E, Lamas, GA, Mark, DB, Boineau, R, Goertz, C, Rosenberg, Y, Nahin, RL, Ouyang, P, Rozema, T, Magaziner, A, Nahas, R, Lewis, EF, Lindblad, L, and Lee, KL. "The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT)." Circulation. Cardiovascular Quality and Outcomes 7, no. 1 (January 2014): 15-24.

PMID
24254885
Full Text

Lamas, GA, Boineau, R, Goertz, C, Mark, DB, Rosenberg, Y, Stylianou, M, Rozema, T, Nahin, RL, Lindblad, L, Lewis, EF, Drisko, J, and Lee, KL. "Oral high-dose multivitamins and minerals after myocardial infarction: A randomized trial." Annals of Internal Medicine 159, no. 12 (December 17, 2013): 797-804.

PMID
24490264
Scholars@Duke

Lamas, GA, Nahin, RL, Lindblad, L, Goertz, C, Boineau, R, Chappell, T, Flaker, G, Rozema, T, Born, T, Stylianou, M, Lewis, EF, Mark, DB, and Lee, KL. "Clinical Benefit of EDTA-based Chelation Therapy and High-dose Oral Multivitamins and Multiminerals in TACT- An Expanded Comparison of 2 Factorial Groups." November 26, 2013.

Scholars@Duke

Escolar, E, Lamas, GA, Mark, DB, Ouyang, P, Magaziner, A, Boineau, R, Miranda, R, Goertz, C, Rosenberg, Y, Nahin, RL, Nahas, R, Lewis, EF, Lindblad, L, and Lee, KL. "Clinical Benefit of EDTA Chelation Therapy in Patients With Diabetes in the Trial to Assess Chelation Therapy (TACT)." November 26, 2013.

Scholars@Duke

Chen, J, Johnson, G, Hellkamp, AS, Anderson, J, Mark, DB, Lee, KL, Bardy, GH, and Poole, JE. "Reply: rapid rate nonsustained ventricular tachycardia found on ICD interrogation: relationship of RR-NSVT to outcomes in the SCD-HeFT trial." Journal of the American College of Cardiology 62, no. 21 (November 2013): 2028-2029. (Letter)

PMID
23994409
Full Text

Lamas, GA, Mark, D, and Lee, KL. "Chelation Therapy and Cardiovascular Outcomes Reply." JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 310, no. 4 (July 24, 2013): 431-432.

PMID
23917300
Full Text

Aoukar, PS, Poole, JE, Johnson, GW, Anderson, J, Hellkamp, AS, Mark, DB, Lee, KL, and Bardy, GH. "No benefit of a dual coil over a single coil ICD lead: evidence from the Sudden Cardiac Death in Heart Failure Trial." Heart Rhythm 10, no. 7 (July 2013): 970-976.

PMID
23562699
Full Text

Pages